PGS Sample Set (PSS): PSS001069

Phenotype All individuals had non-small cell lung cancer (NSCLC) and were receiving immune checkpoint inhibitor (CPI) therapy. Cases were individuals who had experienced immune-related thyroid dysfunction following CPI therapy. A thyroid event after the start of CPI therapy was defined as either (1) incident hypothyroidism or (2) transient incident hyperthyroidism followed by incident hypothyroidism. Incident hypothyroidism was defined as (a) a TSH of ≥ 10 mU/L or (b) TSH of ≥ 5 mU/L with a new prescription of levothyroxine ≥ 50 mcg. Incident hyperthyroidism was defined as TSH < 0.05 mU/L.
Sample Ancestry European, African unspecified, Asian unspecified, Hispanic or Latin American, NR
Additional Ancestry Description European = 506, African unspecified = 22, Asian unspecified = 17, Not reported = 6, Hispanic or Latin American = 10

Sample Numbers

Total number
561 individuals
Detailed numbers
42 cases (7.49%)
519 controls
44.0% Male samples
Participant Follow-up Time Median : 12.0 months
Age of Study Participants
  • Median : 67.0 years
  • Iqr : [60.0, 74.0] years
Sample distribution
Sample gender distribution

Additional information

Cases and controls were obtained from the Dana-Farber Cancer Institute (DFCI)